3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
42
Nivolumab
13
Carboplatin
11
Cyclophosphamide
10
olaparib
7
Paclitaxel
7
Ipilimumab
7
fludarabine
6
Gemcitabine
6
durvalumab
5
lenvatinib
4
cemiplimab
4
atezolizumab
4
Specimen Handling
4
Oxaliplatin
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Fulvestrant
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
veliparib
3
spartalizumab
3
sacituzumab govitecan
3
liposomal doxorubicin
3
avelumab
3
aldesleukin
3
Taxes
3
Interleukin-2
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
bemarituzumab
×
Gynecologic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled